Time to Progression as Evaluated by the Investigator Randomization until the date of disease progression or death (average of 26 weeks) [clinicaltrials_resource:4782c1735426b7236a086e57ffe15a3c]
Time to progression (TTP) is defined as the interval between the date of randomization and the earliest date of progression of disease (PD) or death due to breast cancer. The investigator assessed PD based on radiological PD (imaging data) and clinical symptomatic progress (Response Evaluation Criteria in Solid Tumors [RECIST] Criteria: target lesion (TL), at least a 20% increase in the sum of largest diameter (LD) of TLs or the appearance of one or more new lesions; non-TL (NTL), the appearance of one or more new lesions and/or unequivocal progression of existing NTLs). TTP was assessed in participants who died due to breast cancer or progressed, as assessed by the investigator, as well as in those who were censored and completed follow-up and those who were censored but are still being followed. For censored participants (those without a documented date of disease progression/death due to breast cancer), the date of the last radiographic assessment was used.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Time to Progression as Evaluated by the Investigator Randomization until the date of disease progression or death (average of 26 weeks) [clinicaltrials_resource:4782c1735426b7236a086e57ffe15a3c]
Time to progression (TTP) is defined as the interval between the date of randomization and the earliest date of progression of disease (PD) or death due to breast cancer. The investigator assessed PD based on radiological PD (imaging data) and clinical symptomatic progress (Response Evaluation Criteria in Solid Tumors [RECIST] Criteria: target lesion (TL), at least a 20% increase in the sum of largest diameter (LD) of TLs or the appearance of one or more new lesions; non-TL (NTL), the appearance of one or more new lesions and/or unequivocal progression of existing NTLs). TTP was assessed in participants who died due to breast cancer or progressed, as assessed by the investigator, as well as in those who were censored and completed follow-up and those who were censored but are still being followed. For censored participants (those without a documented date of disease progression/death due to breast cancer), the date of the last radiographic assessment was used.
Bio2RDF identifier
4782c1735426b7236a086e57ffe15a3c
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:4782c1735426b7236a086e57ffe15a3c
measure [clinicaltrials_vocabulary:measure]
Time to Progression as Evaluated by the Investigator
time frame [clinicaltrials_vocabulary:time-frame]
Randomization until the date of disease progression or death (average of 26 weeks)
description
Time to progression (TTP) is d ...... iographic assessment was used.
identifier
clinicaltrials_resource:4782c1735426b7236a086e57ffe15a3c
title
Time to Progression as Evaluat ...... or death (average of 26 weeks)
@en
type
label
Time to Progression as Evaluat ...... 2c1735426b7236a086e57ffe15a3c]
@en